Azathioprine - paediatric & adolescent (non-transplant indications)

Dermatology / Gastroenterology / Rheumatology shared care guideline.

This guideline is relevant to the care of children and adolescents up to the age of 18 or until they transition to adult services.

### Introduction

**Unlicensed indications:** juvenile systemic lupus erythematosus, autoimmune conditions (usually when corticosteroid therapy alone has proved inadequate), vasculitis, severe ulcerative colitis, Crohn's disease, severe eczema.

### Paediatric & adolescent dosage and administration

<table>
<thead>
<tr>
<th>Indications</th>
<th>Dosing schedule (BNFc September 2016)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Juvenile systemic lupus erythematosus, vasculitis, auto-immune conditions usually when corticosteroid therapy alone has proved inadequate</td>
<td>Child 1 month - 18 years initially 1mg/kg daily adjusted according to response to max 3mg/kg daily (consider withdrawal if no improvement within 3 months)</td>
</tr>
<tr>
<td>Severe ulcerative colitis and Crohn's disease</td>
<td>Child 2 - 17 years initially 2mg/kg once daily, then increased if necessary up to 2.5mg/kg once daily</td>
</tr>
<tr>
<td>Severe eczema</td>
<td>1 - 3mg/kg/day</td>
</tr>
</tbody>
</table>

Dosage may need to be reduced in patients with renal and/or mild to moderate hepatic impairment.

**Preparations available:** azathioprine 25mg, 50mg tablets

Where possible, tablets should be prescribed. In exceptional circumstances, an (unlicensed) oral solution may be required. Azathioprine 50mg/5ml is the standard strength that must be used.

### Hospital specialist responsibilities

- Assess if the patient is suitable for treatment with azathioprine.
- Agree shared care with patient's GP and document in patient’s case notes.
- Provide the patient/carer with relevant (preferably written) information on use, side effects and need for monitoring of medication.
- Provide shared care monitoring record booklet if required.
- Undertake baseline tests as indicated in monitoring table.
- Check vaccination history as live vaccines cannot be given while on immunosuppressant treatment.
- Vaccination prior to immune suppression is advised. Please make arrangements to ensure varicella zoster vaccination is provided if appropriate.
- Review results of safety monitoring and request additional tests as required.
- Monitor disease response to treatment and need to continue therapy.
- Continue to review the patient at agreed specified intervals, sending a written summary to the GP whenever the patient is reviewed.
- Provide any other advice or information for the GP if required.
<table>
<thead>
<tr>
<th>Test</th>
<th>Indication</th>
<th>Hospital specialist</th>
<th>GP</th>
<th>Hospital specialist</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pre-treatment baseline</td>
<td></td>
</tr>
<tr>
<td>FBC</td>
<td>Baseline assessment, disease activity scoring &amp; dose adjustment</td>
<td>✓</td>
<td>Every 1 - 2 weeks (as advised by specialist)</td>
<td></td>
</tr>
<tr>
<td>LFTs</td>
<td></td>
<td></td>
<td>Every month</td>
<td></td>
</tr>
<tr>
<td>ESR/CRP</td>
<td>(Rheumatology &amp; Gastroenterology only)</td>
<td></td>
<td>Every 1 - 3 months (as advised by specialist)</td>
<td>As part of annual review or as clinically indicated</td>
</tr>
<tr>
<td>U&amp;Es, serum creatinine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amylase</td>
<td>(Gastroenterology only)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height &amp; weight</td>
<td>Baseline assessment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPMT</td>
<td>To assess suitability for treatment</td>
<td>✓</td>
<td></td>
<td>If clinically indicated</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>To assess for renal disease (proteinuria) or infection</td>
<td></td>
<td>Not routinely required</td>
<td></td>
</tr>
<tr>
<td>Blood pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest x-ray</td>
<td>Baseline assessment, respiratory and TB screening</td>
<td>If clinically indicated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFTs, TB screening if indicated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ask about oral ulceration, sore throat, unexplained rash or unusual bruising/bleeding</td>
<td>✓</td>
<td>At every consultation</td>
<td>✓</td>
<td>If a further DMARD is added as combination therapy, or the dose is increased, the 'First 2 months' schedule should be reinstated. There may be clinical circumstances where the frequency of monitoring may vary and this should be specified by the initiating specialist</td>
</tr>
</tbody>
</table>

**GP responsibilities**

- Prescribe azathioprine.
- Arrange and record ongoing monitoring as advised by specialist (see monitoring table), ensuring practice systems are in place to recall patients for monitoring blood tests.
- Prevent ongoing prescription if patient is not compliant with monitoring. Liaise with specialist if appropriate.
- Report any adverse drug reactions to the initiating specialist and the usual bodies (eg. MHRA/CHM).
- Ensure no drug interactions with other medicines.
- Administer inactivated influenza vaccine annually unless otherwise advised by the initiating specialist. Note the live formulation (eg. Fluenz Tetra®) must not be used.
- Check patient has received pneumococcal vaccine according to BNF or Green Book schedule.
- Provide varicella zoster vaccination if requested by specialist prior to treatment.
- Passive immunization using varicella immunoglobulin (VZIG) should be considered in non-immune patients if exposed to chickenpox or shingles. Contact Regional Virus Laboratory, Royal Group of Hospitals, duty virologist 07889 086 946 for advice if exposure is suspected. For other queries eg. those concerning exposure, infection or any recommendations relating to healthy susceptible household contacts, consult the Green Book and/or take additional advice from Regional Virus Laboratory, Royal Group of Hospitals.
- Ask about oral ulceration, sore throat, unexplained rash or unusual bruising/bleeding at every consultation.
Withhold azathioprine and contact specialist if:

- WCC < 3.5 x 10⁹/L
- Neutrophils < 1.6 x 10⁹/L
- Unexplained eosinophilia > 0.5 x 10⁹/L
- Platelets < 140 x 10⁹/L
- MCV > 105fL, (check B12 & folate & TFT)
- AST/ALT > 3 times the upper limit of normal (for results between 2 - 3 x ULN, continue azathioprine, repeat bloods and seek specialist advice). Minor elevations of AST/ALT are common
- If renal impairment develops
- Unexplained fall in serum albumin
- Oral ulceration / sore throat
- Unexplained rash / abnormal bruising
- New or increasing dyspnoea or dry cough.

Normal reference range may vary slightly between labs.

Results should be recorded in the patient’s shared care monitoring record booklet (where in use).

Please note an unusual fall or rise or a consistent downward or upward trend in any value should prompt review of the patient and extra vigilance. Some patients may have abnormal baseline values, specialist will advise.

### Adverse effects, precautions and contraindications

**General signs of malaise** such as dizziness, diarrhoea, rash, myalgia and arthralgia occur infrequently. If severe or persistent refer to initiating specialist.

**Renal impairment.** Caution is advised regarding adequacy of renal function if azathioprine is to be used concomitantly with NSAIDs, ACE inhibitors or angiotensin II antagonists.

**Infection.** Immunosuppressants can increase susceptibility to infection. It is advisable not to commence or continue treatment with azathioprine when patients have a confirmed or established local or systemic infection. It is advisable to recommence once the infection has been treated. Precise period of discontinuation depends on the nature and severity of infection and the activity of the underlying disease.

**Nausea** can occur initially but can be reduced by taking the tablets after food.

**Blood disorders:** leucopenia, anaemia and thrombocytopenia. GPs should be alert to any oral ulceration, sore throat, unexplained rash or abnormal bruising/bleeding.

**Pancreatitis** has been reported in a small percentage of patients.

**Pregnancy / contraception.** Where applicable for sexually active patients, women of childbearing potential and men receiving azathioprine should be advised to use effective contraception. Patients discovered or planning to become pregnant should be referred to the initiating specialist at the earliest opportunity without discontinuing azathioprine.

**Breastfeeding.** Women being treated with azathioprine should seek specialist advice.

**Cancer risk.** Patients receiving long-term immunosuppressive drugs are at increased risk of developing a malignancy. The most frequently occurring types are lymphoma and skin malignancy. The avoidance of excessive exposure to the sun, and the use of high factor sunscreen and protective clothing are advised. Adherence to population screening programmes is particularly important in this population.

**Live vaccines.** Consult the Green Book and take additional advice from initiating specialist if required.

**Contraindications** include:

- Hypersensitivity to mercaptopurine
- Severe hepatic impairment
- TPMT deficiency - avoid if deficient or reduce dose if low levels.

### Common drug interactions

**Allopurinol** prolongs activity of azathioprine increasing risk of severe myelosuppression. If it must be given concomitantly, it is essential that only a quarter of the usual dose of azathioprine is given.

**Aminosalicylates** (eg. Sulfasalazine) contribute to bone marrow toxicity and increased monitoring may be required

**Febuxostat:** avoid concomitant use.

**Ribavirin:** increases risk of myelosuppression.

**Trimethoprim and co-trimoxazole:** there is a risk of haematological abnormalities.

**Warfarin** effect may be reduced requiring an increased dose of warfarin.

### Communication

For any queries relating to this patient’s treatment with azathioprine, please contact the specialist named at the top of this document.

This information is not inclusive of all prescribing information and potential adverse effects.

Please refer to full prescribing data in the SPC or the BNF.

Date prepared: June 2017  Date of review: June 2022